All In Biotech

Drug Trial Radar · NCT06536517

The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.

A Randomized Controlled Trial to Study the Effects of One-time Intra-operative Dosing of Methadone During Laparoscopic or Robotic Hysterectomy in Reducing Opioid Prescription.

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 7, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. This study aims to find the optimal pain medication plan during and after laparoscopic hysterectomy to eliminate long-term opioid use. Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of Methadone, a longer opioid analgesics, intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries. The investigators hypothesize that this could minimize the need for additional post-operative and outpatient opioid prescriptions and decrease the adverse effects that are associated with the consumption, including new opioid abuse. Intervention group will receive methadone intraoperatively while the other group would receive short-acting opioids (standard).

Conditions

  • Fibroid Uterus

Interventions

  • MethadoneDrug

    Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total post-operative opioid requirements in oral morphine milligram equivalents (MME)Time frame: 1 week

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Johns Hopkins Bayview Medical Center

    Baltimore, Maryland · Recruiting

  • The Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.